Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2023-02-21 17:15:40 UTC |
---|
HMDB ID | HMDB0001406 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Niacinamide |
---|
Description | Niacinamide, also known as nicotinamide (NAM), is a form of vitamin B3 found in food and used as a dietary supplement and medication. Niacinamide belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. The structure of nicotinamide consists of a pyridine ring to which a primary amide group is attached in the meta position. It is an amide of nicotinic acid. As an aromatic compound, it undergoes electrophilic substitution reactions and transformations of its two functional groups. Niacinamide and phosphoribosyl pyrophosphate can be converted into nicotinic acid mononucleotide and phosphate by the enzyme nicotinamide phosphoribosyltransferase. In humans, niacinamide is involved in the metabolic disorder called the nad+ signalling pathway (cancer). Niacinamide is an odorless tasting compound. Outside of the human body, niacinamide is found, on average, in the highest concentration within a few different foods, such as common sages, cow milk, and cocoa beans and in a lower concentration in common pea. Niacinamide has also been detected, but not quantified in several different foods, such as yardlong beans, roselles, apples, oyster mushrooms, and swiss chards. Niacinamide occurs in trace amounts mainly in meat, fish, nuts, and mushrooms, as well as to a lesser extent in some vegetables. It is commonly added to cereals and other foods. Many multivitamins contain 20–30 mg of vitamin B3 and it is also available in higher doses. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. |
---|
Structure | InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9) |
---|
Synonyms | Value | Source |
---|
3-Pyridinecarboxamide | ChEBI | beta-Pyridinecarboxamide | ChEBI | Niacin | ChEBI | Nicotinamid | ChEBI | Nicotinic acid amide | ChEBI | Nicotinsaeureamid | ChEBI | Nikotinamid | ChEBI | Nikotinsaeureamid | ChEBI | Vitamin b3 | ChEBI | Vitamin PP | ChEBI | Nicotinamide | Kegg | b-Pyridinecarboxamide | Generator | Β-pyridinecarboxamide | Generator | Nicotinate amide | Generator | 3-Carbamoylpyridine | HMDB | 3-Pyridinecarboxylic acid amide | HMDB | Acid amide | HMDB | Amid kyseliny nikotinove | HMDB | Amide PP | HMDB | Aminicotin | HMDB | Amixicotyn | HMDB | Amnicotin | HMDB | Austrovit PP | HMDB | Benicot | HMDB | Delonin amide | HMDB | Dipegyl | HMDB | Dipigyl | HMDB | Endobion | HMDB | Factor PP | HMDB | Hansamid | HMDB | Inovitan PP | HMDB | m-(Aminocarbonyl)pyridine | HMDB | Mediatric | HMDB | NAM | HMDB | Nandervit-N | HMDB | Niacevit | HMDB | Niamide | HMDB | Niavit PP | HMDB | Nicamide | HMDB | Nicamina | HMDB | Nicamindon | HMDB | Nicasir | HMDB | Nicobion | HMDB | Nicofort | HMDB | Nicogen | HMDB | Nicomidol | HMDB | Nicosan 2 | HMDB | Nicosylamide | HMDB | Nicota | HMDB | Nicotamide | HMDB | Nicotilamide | HMDB | Nicotililamido | HMDB | Nicotinamida | HMDB | Nicotinamidum | HMDB | Nicotine acid amide | HMDB | Nicotine amide | HMDB | Nicotinic amide | HMDB | Nicotinsaureamid | HMDB | Nicotol | HMDB | Nicotylamide | HMDB | Nicotylamidum | HMDB | Nicovel | HMDB | Nicovit | HMDB | Nicovitina | HMDB | Nicovitol | HMDB | Nicozymin | HMDB | Nictoamide | HMDB | Niko-tamin | HMDB | Niocinamide | HMDB | Niozymin | HMDB | Papulex | HMDB | Pelmin | HMDB | Pelmine | HMDB | Pelonin amide | HMDB | PP-Faktor | HMDB | Propamine a | HMDB | Pyridine-3-carboxylic acid amide | HMDB | Savacotyl | HMDB | Vi-nicotyl | HMDB | Vi-noctyl | HMDB | Witamina PP | HMDB | 3 Pyridinecarboxamide | HMDB | Astra brand OF niacinamide | HMDB | b 3, Vitamin | HMDB | Niacinamide merck brand | HMDB | Pharmagenix brand OF niacinamide | HMDB | b3, Vitamin | HMDB | Enduramide | HMDB | Jenapharm, nicotinsäureamid | HMDB | Niacinamide jenapharm brand | HMDB | Niacinamide pharmagenix brand | HMDB | Jenapharm brand OF niacinamide | HMDB | Nicotinsäureamid jenapharm | HMDB | Vitamin b 3 | HMDB | Merck brand OF niacinamide | HMDB | Niacinamide astra brand | HMDB | Niacinamide | ChEBI |
|
---|
Chemical Formula | C6H6N2O |
---|
Average Molecular Weight | 122.1246 |
---|
Monoisotopic Molecular Weight | 122.048012824 |
---|
IUPAC Name | pyridine-3-carboxamide |
---|
Traditional Name | nicotinamide |
---|
CAS Registry Number | 98-92-0 |
---|
SMILES | NC(=O)C1=CC=CN=C1 |
---|
InChI Identifier | InChI=1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9) |
---|
InChI Key | DFPAKSUCGFBDDF-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Pyridines and derivatives |
---|
Sub Class | Pyridinecarboxylic acids and derivatives |
---|
Direct Parent | Nicotinamides |
---|
Alternative Parents | |
---|
Substituents | - Nicotinamide
- Heteroaromatic compound
- Primary carboxylic acid amide
- Carboxamide group
- Azacycle
- Carboxylic acid derivative
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 130 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 500 mg/mL at 25 °C | Not Available | LogP | -0.37 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Niacinamide,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC=CN=C1 | 1450.6 | Semi standard non polar | 33892256 | Niacinamide,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC=CN=C1 | 1461.6 | Standard non polar | 33892256 | Niacinamide,1TMS,isomer #1 | C[Si](C)(C)NC(=O)C1=CC=CN=C1 | 1821.4 | Standard polar | 33892256 | Niacinamide,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC=CN=C1)[Si](C)(C)C | 1493.5 | Semi standard non polar | 33892256 | Niacinamide,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC=CN=C1)[Si](C)(C)C | 1567.1 | Standard non polar | 33892256 | Niacinamide,2TMS,isomer #1 | C[Si](C)(C)N(C(=O)C1=CC=CN=C1)[Si](C)(C)C | 1791.6 | Standard polar | 33892256 | Niacinamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC=CN=C1 | 1684.5 | Semi standard non polar | 33892256 | Niacinamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC=CN=C1 | 1639.3 | Standard non polar | 33892256 | Niacinamide,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC(=O)C1=CC=CN=C1 | 1996.3 | Standard polar | 33892256 | Niacinamide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC=CN=C1)[Si](C)(C)C(C)(C)C | 1944.3 | Semi standard non polar | 33892256 | Niacinamide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC=CN=C1)[Si](C)(C)C(C)(C)C | 1956.2 | Standard non polar | 33892256 | Niacinamide,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C(=O)C1=CC=CN=C1)[Si](C)(C)C(C)(C)C | 2017.4 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS) | splash10-004i-0900000000-acb6a21304b0c09c8472 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-004r-0900000000-ce86dcff0153b66dd538 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (1 TMS) | splash10-004i-9500000000-790385e574240b8d39de | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-MS (2 TMS) | splash10-0udi-2910000000-d760b65bb76d6464038e | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-MS (1 TMS) | splash10-004i-4900000000-47c6f72d1bb5465c1376 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide EI-B (Non-derivatized) | splash10-0kor-9800000000-1809e537780b814af0c9 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide EI-B (Non-derivatized) | splash10-0kor-9800000000-c4a5ff5285417499eff8 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide EI-B (Non-derivatized) | splash10-004i-0900000000-0e84a60cc2a2d44704f4 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Non-derivatized) | splash10-004i-0900000000-acb6a21304b0c09c8472 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Non-derivatized) | splash10-004r-0900000000-ce86dcff0153b66dd538 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Non-derivatized) | splash10-004i-9500000000-790385e574240b8d39de | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-MS (Non-derivatized) | splash10-0udi-2910000000-d760b65bb76d6464038e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-MS (Non-derivatized) | splash10-004i-4900000000-47c6f72d1bb5465c1376 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - Niacinamide GC-EI-TOF (Non-derivatized) | splash10-004i-0900000000-23a567506bfbc259e77c | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Niacinamide GC-MS (Non-derivatized) - 70eV, Positive | splash10-05fr-8900000000-931c139355be3ef594f2 | 2016-09-22 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Niacinamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Niacinamide GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0kor-9600000000-2b1c5667d92bc1b80b36 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-00di-2900000000-72a7c92eb2667f5b6c3f | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-001i-9000000000-6486d230a4a2fd4bab0e | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-001i-9000000000-6486d230a4a2fd4bab0e | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide EI-B (HITACHI M-80) , Positive-QTOF | splash10-0kor-9800000000-89d56b6cb7e033699d24 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ (API3000, Applied Biosystems) 10V, Positive-QTOF | splash10-00di-0900000000-eed71abbb10ba926c13d | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ (API3000, Applied Biosystems) 20V, Positive-QTOF | splash10-00di-3900000000-0c62aa6aba6e23b6c195 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ (API3000, Applied Biosystems) 30V, Positive-QTOF | splash10-001i-9100000000-4357a8833611d1756c59 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ (API3000, Applied Biosystems) 40V, Positive-QTOF | splash10-001i-9000000000-c9685717817d0081fe6d | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ (API3000, Applied Biosystems) 50V, Positive-QTOF | splash10-0fc0-9000000000-ec0ccca306f38cf72a78 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive-QTOF | splash10-00di-4900000000-f6d71a6c467f84ddd6ab | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positive-QTOF | splash10-001i-9100000000-62c4bd312efbfa37d1a1 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive-QTOF | splash10-00di-4900000000-05714b528dc84942b9db | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, Positive-QTOF | splash10-001i-9100000000-edb6a77c0dfdcbdacc5d | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ , positive-QTOF | splash10-00di-0900000000-eed71abbb10ba926c13d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ , positive-QTOF | splash10-00di-3900000000-0c62aa6aba6e23b6c195 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ , positive-QTOF | splash10-001i-9100000000-4357a8833611d1756c59 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ , positive-QTOF | splash10-001i-9000000000-c9685717817d0081fe6d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-QQ , positive-QTOF | splash10-0fc0-9000000000-ec0ccca306f38cf72a78 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Niacinamide LC-ESI-ITFT , positive-QTOF | splash10-00di-0900000000-960acce7ead55399b5db | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Niacinamide 10V, Positive-QTOF | splash10-00di-0900000000-2c7ec333d35eb740520a | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Niacinamide 20V, Positive-QTOF | splash10-0089-9600000000-466f98885e2efba73575 | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Niacinamide 40V, Positive-QTOF | splash10-0ue9-9200000000-6ef8d7e5edcdd0b02758 | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Niacinamide 10V, Negative-QTOF | splash10-00di-1900000000-f38177aa475e58941088 | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Niacinamide 20V, Negative-QTOF | splash10-00fr-9800000000-6a883d82fcd7c450f6ce | 2015-05-27 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Niacinamide 40V, Negative-QTOF | splash10-0006-9000000000-882d0c59d946a5087b9f | 2015-05-27 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 600 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Disease References | Uremia |
---|
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
| Crohn's disease |
---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| Ulcerative colitis |
---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| Diverticular disease |
---|
- Tursi A, Mastromarino P, Capobianco D, Elisei W, Miccheli A, Capuani G, Tomassini A, Campagna G, Picchio M, Giorgetti G, Fabiocchi F, Brandimarte G: Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon. J Clin Gastroenterol. 2016 Oct;50 Suppl 1:S9-S12. doi: 10.1097/MCG.0000000000000626. [PubMed:27622378 ]
| Colorectal cancer |
---|
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
|
|
---|
General References | - Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Rybak ME, Pfeiffer CM: Clinical analysis of vitamin B(6): determination of pyridoxal 5'-phosphate and 4-pyridoxic acid in human serum by reversed-phase high-performance liquid chromatography with chlorite postcolumn derivatization. Anal Biochem. 2004 Oct 15;333(2):336-44. [PubMed:15450810 ]
- Draelos ZD, Ertel K, Berge C: Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005 Aug;76(2):135-41. [PubMed:16209160 ]
- Soma Y, Kashima M, Imaizumi A, Takahama H, Kawakami T, Mizoguchi M: Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 2005 Mar;44(3):197-202. [PubMed:15807725 ]
- Authors unspecified: Final report of the safety assessment of niacinamide and niacin. Int J Toxicol. 2005;24 Suppl 5:1-31. [PubMed:16596767 ]
- Draelos ZD, Matsubara A, Smiles K: The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006 Jun;8(2):96-101. [PubMed:16766489 ]
- Schulpis K, Spiropoulos A, Gavrili S, Karikas G, Grigori C, Vlachos G, Papassotiriou I: Maternal - neonatal folate and vitamin B12 serum concentrations in Greeks and in Albanian immigrants. J Hum Nutr Diet. 2004 Oct;17(5):443-8. [PubMed:15357698 ]
- Yang L, Yao Y, Shi Y, Wang X, Shi J: [Expression of nicotinamide edenine dinucleotide dehydrogenase gene in placenta of patients with pregnancy induced hypertension]. Zhonghua Fu Chan Ke Za Zhi. 2002 Nov;37(11):660-2. [PubMed:12487919 ]
- Sonee M, Martens JR, Mukherjee SK: Nicotinamide protects HCN2 cells from the free radical generating toxin, tertiary butylhydroperoxide (t-BuOOH). Neurotox Res. 2002 Nov-Dec;4(7-8):595-599. [PubMed:12709297 ]
- Bayraktar F, Dereli D, Ozgen AG, Yilmaz C: Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J. 2004 Dec;51(6):601-8. [PubMed:15644580 ]
- Sonee M, Martens JR, Evers MR, Mukherjee SK: The effect of tertiary butylhydroperoxide and nicotinamide on human cortical neurons. Neurotoxicology. 2003 Jun;24(3):443-8. [PubMed:12782109 ]
- Anisimov AG, Bolotnikov IA: [Nicotinamide decreases DNA destabilization in K562 cells treated with AlF(-4)]. Tsitologiia. 1997;39(9):822-8. [PubMed:9518388 ]
- Matuoka K, Chen KY, Takenawa T: Rapid reversion of aging phenotypes by nicotinamide through possible modulation of histone acetylation. Cell Mol Life Sci. 2001 Dec;58(14):2108-16. [PubMed:11814060 ]
- Bartalena L, Tanda ML, Piantanida E, Lai A: Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors. 2003;19(3-4):155-63. [PubMed:14757966 ]
- Bissett DL, Oblong JE, Berge CA: Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005 Jul;31(7 Pt 2):860-5; discussion 865. [PubMed:16029679 ]
- Baeza N, Moriscot C, Figarella C, Guy-Crotte O, Vialettes B: Reg protein: a potential beta-cell-specific growth factor? Diabetes Metab. 1996 Jul;22(4):229-34. [PubMed:8767167 ]
- Hoskin PJ, Rojas AM, Phillips H, Saunders MI: Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer. 2005 Jun 1;103(11):2287-97. [PubMed:15834926 ]
- Rembold CM: Combination therapy of dyslipidemia in non-insulin-dependent diabetes mellitus and the metabolic syndrome. Curr Diab Rep. 2004 Oct;4(5):330-4. [PubMed:15461896 ]
- Kawasaki E, Abiru N, Eguchi K: Prevention of type 1 diabetes: from the view point of beta cell damage. Diabetes Res Clin Pract. 2004 Dec;66 Suppl 1:S27-32. [PubMed:15563975 ]
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70. doi: 10.1681/ASN.2011121175. Epub 2012 May 24. [PubMed:22626821 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
---|